RT Journal Article
SR Electronic
T1 Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.13.21258860
DO 10.1101/2021.06.13.21258860
A1 Soto, Jessica Torres
A1 Hughes, J. Weston
A1 Sanchez, Pablo Amador
A1 Perez, Marco
A1 Ouyang, David
A1 Ashley, Euan
YR 2021
UL http://medrxiv.org/content/early/2021/06/15/2021.06.13.21258860.abstract
AB Determining the etiology of left ventricular hypertrophy (LVH) can be challenging due to the similarity in clinical presentation and cardiac morphological features of diverse causes of disease. In particular, distinguishing individuals with hypertrophic cardiomyopathy (HCM) from the much larger set of individuals with manifest or occult hypertension (HTN) is of major importance for family screening and the prevention of sudden death. We hypothesized that deep learning based joint interpretation of 12 lead electrocardiograms and echocardiogram videos could augment physician interpretation. We chose not to train on proximate data labels such as physician over-reads of ECGs or echocardiograms but instead took advantage of electronic health record derived clinical blood pressure measurements and diagnostic consensus (often including molecular testing) among physicians in an HCM center of excellence. Using over 18,000 combined instances of electrocardiograms and echocardiograms from 2,728 patients, we developed LVH-Fusion. On held-out test data, LVH-Fusion achieved an F1-score of 0.71 in predicting HCM, and 0.96 in predicting HTN. In head-to-head comparison with human readers LVH-Fusion had higher sensitivity and specificity rates than its human counterparts. Finally, we use explainability techniques to investigate local and global features that positively and negatively impact LVH-Fusion prediction estimates providing confirmation from unsupervised analysis the diagnostic power of lateral T wave inversion on the ECG and proximal septal hypertrophy on the echocardiogram for HCM. In conclusion, these results show that deep learning can provide effective physician augmentation in the face of a common diagnostic dilemma with far reaching implications for the prevention of sudden cardiac death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThe funding of this study was provided through Institutional funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yes, we had an approved IRB for this study through Stanford University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the code for LVH-Fusion will be available at https://github.com/AshleyLab/lvh-fusion/ after publication. The data that support the findings of this study are available on request from the corresponding author upon approval of data sharing committees of the respective institutions.